Glutaminyl based DPIV inhibitors
The present invention provides compounds of the formula: wherein X=CH 2 or S or pharmaceutical acceptable salts thereof useful for treating conditions mediated by DPIV or DPIV-like enzymes, such as arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases.
1. Acid addition salts of a compound of formula:
wherein X=CH 2 or S and wherein the acid addition salt is the hydrochloric salt.
2. A compound glutaminyl thiazolidine hydrocbioride.
3. The compound glutaminyl pyrrolidine hydrochloride.
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or diluent and the compound of claim 1 .
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or diluent and the compound of claim 2 .
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or diluent and the compound of claim 3 .
7. A method for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for the treatment of diseases or conditions related to dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzymes selected from the group consisting of non-insulin-dependent diabetes mellitus, arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases comprising administering to a mammal in need of such treatment a therapeuticaily effective amount of the compound according to claim 1 .
8. A method for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for the treatment of diseases or conditions related to dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzymes selected from the group consisting of non-insulin-dependent diabetes mellitus, arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases comprising admninisteting to a mammal in need of such treatment a therapeutically effective amount of the compound accordiug to claim 2 .
9. A method for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for the treatment of diseases or conditions related to dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzymes selected from the group consisting of non-insulin-dependent diabetes mellitus, arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases comprising administering to a mammal in need of such treatment a therapeutically effective amount of the compound according to claim 3 .
10. A method for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for the treatment of diseases or conditions related to dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzymes selected from the group consisting of non-insulin-dependent diabetes mellitus, arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases comprising administering to a mammal in need of such treatment a therapeutically effective amount of the composition according to claim 4 .
11. A method for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for the treatment of diseases or conditions related to dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzymes selected from the group consisting of non-insulin-dependent diabetes mellitus, arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases comprising administering to a mammal in need of such treatment a therapeutically effective amount of the composition according to claim 5 .
12. A method for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for the treatment of diseases or conditions related to dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzymes selected from the group consisting of non-insulin-dependent diabetes mellitus, arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases comprising administering to a mammal in need of such treatment a therapeutically effective amount of the composition according to claim 6 .
13. A method for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for lowering elevated blood glucose levels in mammals resulting from food intake comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim 1 .
14. A method for inhibiting dipeptidyI peptidase IV or dipeptidyl peptidase IV-like enzyme activity for lowering elevated blood glucose levels in mammals resulting from food intake comprising administering to a mammal in need of such treatment a therapeutically effective amount of the compound according to claim 2 .
15. The method according to claim 8 for the treatment of a disease or condition selected from non-insulin-dependent diabetes mellitus, artbttis and obesity.
16. A method for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for lowering elevated blood glucose levels in mammals resulting from food intake comprising administering to a mammal in need of such treatment a therapeutically effective amount of the compound according to claim 3 .
17. The method according to claim 7 for the treatment of a disease or condition selected from non-insulin-dependent diabetes mellitus, arthritis and obesity.
18. The method according to claim 9 for the treatment of a disease or condition selected from non-insulin-dependent diabetes mellitus, arthritis and obesity.